Evidence map›Paper›PMID 33963442›Full record

ReviewCellular and molecular life sciences : CMLS2021

Nanoparticle-based approaches to target the lymphatic system for antitumor treatment.

Xingzhou Peng, Junjie Wang, Feifan Zhou, Qian Liu, Zhihong Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cellular and molecular life sciences : CMLS, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Review
  3. Condensate nanovaccine adjuvants augment CD8Signal transduction and targeted therapy · 2025
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xingzhou Peng *School of Biomedical Engineering, Hainan University, Haikou, 570228, Hainan, China.
Junjie Wang *Britton Chance Center and MoE Key Laboratory for Biomedical Photonics, School of Engineering Sciences, Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology, Wuhan, 430074, Hubei, China.
Feifan ZhouSchool of Biomedical Engineering, Hainan University, Haikou, 570228, Hainan, China.
Qian LiuSchool of Biomedical Engineering, Hainan University, Haikou, 570228, Hainan, China. qliu@hainanu.edu.cn.
Zhihong ZhangSchool of Biomedical Engineering, Hainan University, Haikou, 570228, Hainan, China. czyzzh@hust.edu.cn.

Funding

Hainan University KYQD(ZR)19107Hainan University RZ2000007352Wuhan National Laboratory for Optoelectronics Innovation Fund
6 · The paper itself

Abstract

Immunotherapies have been established as safe and efficient modalities for numerous tumor treatments. The lymphatic system, which is an important system, can modulate the immune system via a complex network, which includes lymph nodes, vessels, and lymphocytes. With the deepening understanding of tumor immunology, a plethora of immunotherapies, which include vaccines, photothermal therapy, and photodynamic therapy, have been established for antitumor treatments. However, the deleterious off-target effects and nonspecific targeting of therapeutic agents result in low efficacy of immunotherapy. Fortunately, nanoparticle-based approaches for targeting the lymphatic system afford a unique opportunity to manufacture drugs that can simultaneously tackle both aspects, thereby improving tumor treatments. Over the past decades, great strides have been made in the development of DC vaccines and nanomedicine as antitumor treatments in the field of lymphatic therapeutics and diagnosis. In this review, we summarize the current strategies through which nanoparticle technology has been designed to target the lymphatic system and describe applications of lymphatic imaging for the diagnosis and image-guided surgery of tumor metastasis. Moreover, improvements in the tumor specificity of nanovaccines and medicines, which have been realized through targeting or stimulating the lymphatic system, can provide amplified antitumor immune responses and reduce side effects, thereby promoting the paradigm of antitumor treatment into the clinic to benefit patients.

Indexed as

NanomedicineAnimalsAntineoplastic AgentsHumansImmunotherapyLymphatic SystemNanoparticlesNeoplasmsAntineoplastic AgentsCombinational immunotherapyDC vaccineImage-guided therapyLymphatic targetingLymphoscintigraphyNanoplatformTumor metastasis

Identifiers

PMID33963442
PMCPMC11072902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.